NCT00183820 · OUTCOME

Overall Survival

Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 95% Confidence Interval
Time frame: Through study completion, about 9 years

What was measured

Measuring Overall Survival

Groups in this outcome

Paclitaxel, Gemcitabine, and Oxaliplatin

paclitaxel, gemcitabine, and oxaliplatin: 1. Paclitaxel 170 mg/m2 IV d 1 14 days 2. Gemcitabine 800 mg/m2 IV d 1 14 days 3. Oxaliplatin 100 mg/m2 IV d 1 14 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Paclitaxel, Gemcitabine, and Oxaliplatin	30

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Paclitaxel, Gemcitabine, and Oxaliplatin	18.3	Not reported	12.0	71.8	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
12.0
upper Limit
71.8
value
18.3

denoms

counts
group Id
OG000
value
30
units
Participants

description

Measuring Overall Survival

dispersion Type

95% Confidence Interval

groups

description
paclitaxel, gemcitabine, and oxaliplatin: 1. Paclitaxel 170 mg/m2 IV d 1 14 days 2. Gemcitabine 800 mg/m2 IV d 1 14 days 3. Oxaliplatin 100 mg/m2 IV d 1 14 days
id
OG000
title
Paclitaxel, Gemcitabine, and Oxaliplatin

param Type

MEDIAN

reporting Status

POSTED

time Frame

Through study completion, about 9 years

title

Overall Survival

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice